ReviewArrhythmia & electrophysiology review2018
Pharmacological Therapy in Brugada Syndrome.
Review in Arrhythmia & electrophysiology review, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 41 citations in OpenAlex.
- Type 1 Brugada Pattern Triggered by Low-Grade Fever: Implications for Diagnosis and Risk Stratification.International journal of molecular sciences · 2026Article
- Current Perspective for Atrial Fibrillation in Patients with Brugada Syndrome: A Comprehensive Review.Reviews in cardiovascular medicine · 2025Review
- Brugada syndrome.Nature reviews. Disease primers · 2025Review
- Brugada syndrome precipitated by uncomplicated malaria treated with dihydroartemisinin piperaquine: a case report.Malaria journal · 2024Article
- Zebrafish as a Model System for Brugada Syndrome.Reviews in cardiovascular medicine · 2024Review
- Bepridil monotherapy failed to prevent coronary vasospasm in a Brugada syndrome patient.Oxford medical case reports · 2022Article
- Electrical Storm in a Patient with Brugada Syndrome and Coronavirus Disease 2019.The Journal of innovations in cardiac rhythm management · 2022Article
- Article
- Expert consensus on acute management of ventricular arrhythmias - VT network Austria.International journal of cardiology. Heart & vasculature · 2021Review
- Brugada Syndrome: Presentation and Management of the Atypical Patient in the Emergent Setting.Clinical practice and cases in emergency medicine · 2020Article
- Refractoriness to subcutaneous implantable cardioverter defibrillator after frequent therapies for ventricular fibrillation storms in a Brugada syndrome case.BMC cardiovascular disorders · 2020Article
- Catheter ablation for monomorphic ventricular tachycardia in Brugada syndrome patients: detailed characteristics and long-term follow-up.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2020Article
- Current Controversies and Challenges in Brugada Syndrome.European cardiology · 2019Review
- Questioning the Perpetrator: The Evidence Is in the Electrocardiogram.JACC. Case reports · 2019Article
- Insights for Stratification of Risk in Brugada Syndrome.European cardiology · 2019Review
- Brugada Syndrome: Clinical Features, Risk Stratification, and Management.Heart views : the official journal of the Gulf Heart AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brugada syndrome (BrS) is a cardiac disease caused by an inherited ion channelopathy associated with a propensity to develop ventricular fibrillation. Implantable cardioverter defibrillator implantation is recommended in BrS, based on the clinical presentation in the presence of diagnostic ECG criteria. Implantable cardioverter defibrillator implantation is not always indicated or sufficient in BrS, and is associated with a high device complication rate. Pharmacological therapy aimed at rebalancing the membrane action potential can prevent arrhythmogenesis in BrS. Quinidine, a class 1A antiarrhythmic drug with significant Ito blocking properties, is the most extensively used drug for the prevention of arrhythmias in BrS. The present review provides contemporary data gathered on all drugs effective in the therapy of BrS, and on ineffective or contraindicated antiarrhythmic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.